Federated Hermes
BCAX

Federated Hermes’s Bicara Therapeutics BCAX Stock Holding History

Federated Hermes’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
+15,253
New +$340K ﹤0.01% 1356
2025
Q4 		– Sell
-667
Closed -$10.5K – 2247
2025
Q3 		$10.5K Buy
667
+382
+134% +$4.28K ﹤0.01% 1872
2025
Q2 		$2.65K Sell
285
-11,715
-98% -$140K ﹤0.01% 1945
2025
Q1 		$156K Buy
12,000
+4,000
+50% +$53.1K ﹤0.01% 1526
2024
Q4 		$139K Hold
8,000
– – ﹤0.01% 1530
2024
Q3 		$204K Buy
+8,000
New +$204K ﹤0.01% 1477

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Federated Hermes's BCAX Position: Q2 2026 in Review

Federated Hermes opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 15,253 shares worth $453K. The stake represents ﹤0.01% of the portfolio and ranks #1356 among its holdings. This is a return to the name: Federated Hermes previously reported a position in BCAX as recently as Q3 2025.

Federated Hermes first reported a position in BCAX in Q3 2024 and has held it in 6 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Federated Hermes held 15,253 shares of Bicara Therapeutics worth $453K as of Q2 2026.
  • Bicara Therapeutics was a new Federated Hermes position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1356 holding.
  • Federated Hermes first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.